| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
|
Curigliano, Giuseppe
|
|
2018
|
19 |
4 |
p. 434-436
|
artikel
|
| 2 |
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
|
Loibl, Sibylle
|
|
2018
|
19 |
4 |
p. 497-509
|
artikel
|
| 3 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
|
De Placido, Sabino
|
|
2018
|
19 |
4 |
p. 474-485
|
artikel
|
| 4 |
Adjuvant aromatase inhibition: more options for patients
|
Dirix, Luc Y
|
|
2018
|
19 |
4 |
p. 431-432
|
artikel
|
| 5 |
Adjuvant therapy in colon cancer: less is more
|
Ilson, David H
|
|
2018
|
19 |
4 |
p. 442-443
|
artikel
|
| 6 |
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|
Maio, Michele
|
|
2018
|
19 |
4 |
p. 510-520
|
artikel
|
| 7 |
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
|
Huet, Sarah
|
|
2018
|
19 |
4 |
p. 549-561
|
artikel
|
| 8 |
Aiming for complete responses in renal-cell carcinoma
|
Grünwald, Viktor
|
|
2018
|
19 |
4 |
p. 428-429
|
artikel
|
| 9 |
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
|
Lin, Jessica J
|
|
2018
|
19 |
4 |
p. 438-439
|
artikel
|
| 10 |
Can umbralisib bring PI3Kδ out of the shadows?
|
Barrientos, Jacqueline C
|
|
2018
|
19 |
4 |
p. 432-434
|
artikel
|
| 11 |
Chemotherapy medication errors
|
Weingart, Saul N
|
|
2018
|
19 |
4 |
p. e191-e199
|
artikel
|
| 12 |
Colorectal adenoma risk in childhood cancer survivors
|
Burki, Talha Khan
|
|
2018
|
19 |
4 |
p. e189
|
artikel
|
| 13 |
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
|
Tang, Lin-Quan
|
|
2018
|
19 |
4 |
p. 461-473
|
artikel
|
| 14 |
Correction to Lancet Oncol 2018; 19: 295–309
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 15 |
Correction to Lancet Oncol 2018; 19: 474–85
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 16 |
Correction to Lancet Oncol 2018; 19: 434–36
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 17 |
Correction to Lancet Oncol 2018; 19: 510–20
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 18 |
Correction to Lancet Oncol 2013; 14: 1067–76
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 19 |
Correction to Lancet Oncol 2017; 18: 1221–37
|
|
|
2018
|
19 |
4 |
p. e184
|
artikel
|
| 20 |
Dasatinib in paediatric chronic myeloid leukaemias
|
Venkatesan, Priya
|
|
2018
|
19 |
4 |
p. e188
|
artikel
|
| 21 |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Garassino, Marina Chiara
|
|
2018
|
19 |
4 |
p. 521-536
|
artikel
|
| 22 |
EMA guidance on radium-223 dichloride in prostate cancer
|
Gourd, Elizabeth
|
|
2018
|
19 |
4 |
p. e190
|
artikel
|
| 23 |
Genetic testing for young women with breast cancer
|
Metcalfe, Kelly
|
|
2018
|
19 |
4 |
p. e182
|
artikel
|
| 24 |
Genetic testing for young women with breast cancer – Authors' reply
|
Eccles, Diana M
|
|
2018
|
19 |
4 |
p. e183
|
artikel
|
| 25 |
Guidelines for sub-Saharan Africa: a call for evidence
|
Painschab, Matthew
|
|
2018
|
19 |
4 |
p. 445-446
|
artikel
|
| 26 |
Larotrectinib in TRK fusion-positive cancers
|
Burki, Talha Khan
|
|
2018
|
19 |
4 |
p. e187
|
artikel
|
| 27 |
Medication overuse in oncology: current trends and future implications for patients and society
|
Schleicher, Stephen M
|
|
2018
|
19 |
4 |
p. e200-e208
|
artikel
|
| 28 |
Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?
|
Blanchard, Pierre
|
|
2018
|
19 |
4 |
p. 429-431
|
artikel
|
| 29 |
New interventions offer prostate cancer hope
|
The Lancet Oncology,
|
|
2018
|
19 |
4 |
p. 427
|
artikel
|
| 30 |
Oncology drugs in the crosshairs of pharmaceutical crime
|
Venhuis, Bastiaan J
|
|
2018
|
19 |
4 |
p. e209-e217
|
artikel
|
| 31 |
Opportunities for improving oncology care
|
Syrjala, Karen L
|
|
2018
|
19 |
4 |
p. 449
|
artikel
|
| 32 |
Periosteal aneurysmal bone cyst
|
Alraiyes, Thamer M
|
|
2018
|
19 |
4 |
p. e218
|
artikel
|
| 33 |
Possible X chromosome-linked transmission of ovarian cancer
|
Venkatesan, Priya
|
|
2018
|
19 |
4 |
p. e185
|
artikel
|
| 34 |
Predicting early relapse in follicular lymphoma: have we turned a corner?
|
Araf, Shamzah
|
|
2018
|
19 |
4 |
p. 441-442
|
artikel
|
| 35 |
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
|
Choueiri, Toni K
|
|
2018
|
19 |
4 |
p. 451-460
|
artikel
|
| 36 |
Slogans and donor pages of cancer centres: do they convey discordant messages?
|
Hahn, Ezra
|
|
2018
|
19 |
4 |
p. 447-448
|
artikel
|
| 37 |
The brim of uncertainty in adjuvant treatment of melanoma
|
Warner, Allison Betof
|
|
2018
|
19 |
4 |
p. 436-437
|
artikel
|
| 38 |
The NHS and migrant patients with cancer
|
Williams, Sophie
|
|
2018
|
19 |
4 |
p. 444-445
|
artikel
|
| 39 |
The rise and fall of the wellness warriors
|
Stirrups, Robert
|
|
2018
|
19 |
4 |
p. 450
|
artikel
|
| 40 |
Ultra-processed foods might increase cancer risk
|
Gourd, Elizabeth
|
|
2018
|
19 |
4 |
p. e186
|
artikel
|
| 41 |
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
|
Burris III, Howard A
|
|
2018
|
19 |
4 |
p. 486-496
|
artikel
|
| 42 |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
|
Iveson, Timothy J
|
|
2018
|
19 |
4 |
p. 562-578
|
artikel
|
| 43 |
Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial
|
Höckel, Michael
|
|
2018
|
19 |
4 |
p. 537-548
|
artikel
|
| 44 |
Vulvar field resection: innovative procedure or same old?
|
Zigras, Tiffany
|
|
2018
|
19 |
4 |
p. 439-441
|
artikel
|
Tijdschrift beschrijving